Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist

  title={Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist},
  author={Kazumi Noguchi and Hiroji Uemura and Masao Harada and Takeshi Miura and Masatoshi Moriyama and Hiroshi Fukuoka and Kazuo Kitami and Masahiko Hosaka},
  journal={International Journal of Clinical Oncology},
AbstractBackground. A prospective randomized study was designed to determine whether flutamide (FLU) administered before treatment with a luteinizing hormone-releasing hormone agonist (LH-RHa) prevented prostate-specific antigen (PSA) flare in prostate cancer patients. Methods. Prostate cancer patients were randomized into two groups and received either FLU (n = 11) or no pretreatment (n = 13) for 2 weeks before the initial injection of LH-RHa. LH-RHa (every 4 weeks) and FLU (every day) were… 
Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials
Degarelix monotherapy produced a more favorable effect on PSA PFS outcomes than a LHRH agonist + AA flare protection therapy in patients with prostate cancer when a case-control analysis was used to compensate for differences between treatment groups.
Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy
Evidence is shown that co-medication with dexamethasone/prednisolone and/or estramustine itself can induce an initial PSA flare-up via androgen receptor mutations, and Chemotherapy should be continued a minimum of six weeks before removing patients from a docetaxel-based regimen.
Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel
An initial rise of prostate-specific antigen under docetaxel therapy in hormone-refractory prostate cancer does not indicate therapeutic failure and should not lead to early withdrawal from therapy in the absence of clinical signs of progression.
Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer
This report suggests that a flare does not necessarily indicate lack of response to 223RaCl2 therapy, and the tumor burden reduction, expressed by ΔTLF10 and ΔFTV10, was more evident within PSA flare group below baseline than non-responders.
Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.
This retrospective study evaluates the prognostic role of early PSA drop in metastatic castration resistant prostate cancer patients receiving abiraterone acetate (AA) or enzalutamide (E) and found that mCRPC patients treated with AA or E, in docetaxel-naïve or post-docetaxe setting, had significantly better OS and PFS.
Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database
Although there is no FDA indication for BIC use as monotherapy, 44% of patients in this study used BIC alone or as part of CAB followed by monotherapy; further research is necessary to understand the outcomes of BIC utilization in these settings, particularly compared with newer second-generation anti-androgens.


Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Results clearly demonstrate that pretreatment with DES-P 300 mg daily or CMA 100 mg daily for 2 weeks is quite effective to prevent disease flare after the first administration of L in patients with prostatic cancer.
Pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing-hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate.
CMA lead-in therapy suppressed bone pain and serum levels of luteinizing hormone, testosterone and prostate-specific antigen levels and suppressed the transient increases in these levels associated with the initiation of therapy.
Luteinizing hormone‐releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low‐dose diethylstilbestrol
In response to the first administration of a luteinizing hormone‐releasing hormone (LHRH) agonist, the secretion of pituitary gonadotropin increases sharply and gives rise to a transient surge in the concentration of serum testosterone, which results in the onset of clinical symptoms and signs of tumor flare in 5% of patients.
Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
In patients with histologically confirmed prostate cancer, oestrogen priming with diethylstilboestrol for 4 weeks prior to the first injection of the LHRH agonist Zoladex prevented any rise in the serum testosterone concentration.
Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.
20 Breuer AC, Furlan AJ, Hanson MR, et al. Neurologic complications of open heart surgery. Cleve Clin Q 1981;48:205-6. 21 Breuer AC, Furlan AJ, Hanson MR, et al. Central nervous system complications